Citi analyst Patrick Donnelly lowered the firm’s price target on 10x Genomics to $60 from $75 and keeps a Buy rating on the shares post the Q3 report. The analyst says Xenium placements and orders continue to accelerate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG:
- 10x Genomics raises FY23 revenue view to $610M-$625M from $580M-$600M
- 10x Genomics reports Q3 EPS (79c), consensus (46c)
- 10x Genomics Reports Third Quarter 2023 Financial Results
- 10x Genomics: UPC declines to issue second injunction against NanoString
- 10x Genomics price target lowered to $47 from $66 at Barclays